India, July 22 -- Arrowhead Pharmaceuticals, Inc. (ARWR) shares surged $17.98, or 24.13 percent, to $92.50 on Wednesday, after the company reported positive topline results from its pivotal Phase 3 SHASTA-3 and SHASTA-4 studies evaluating plozasiran in patients with severe hypertriglyceridemia.
The stock opened at $85.39 and traded between $84.36 and $95.49 during the session. It has traded in a 52-week range of $15.01 to $95.49. Trading volume reached 2.62 million shares, compared with an average daily volume of 2.11 million shares.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });
Both Phase 3 trials met their primary endpoint of reducing triglycerides versus placebo and achieved all prespecified seco...